Targeting AKT with the proapoptotic peptide, TAT-CTMP: A novel strategy for the treatment of human pancreatic adenocarcinoma

Keyphrases

• Human Pancreatic Adenocarcinoma 100%
• Pro-apoptotic Peptide 100%
• Carboxyl Terminal 100%
• Pancreatic Adenocarcinoma 85%
• Apoptosis 57%
• Active caspase-3 42%
• Gemcitabine 28%
• Radiation Therapy 28%
• Pancreas Cancer 28%
• Tumor Necrosis Factor-α 14%
• Therapeutic Implications 14%
• Phosphoinositide 3-kinase (PI3K) 14%
• Effective Treatment 14%
• Recombinant 14%
• High Dose 14%
• Tumor Cells 14%
• Negative Control 14%
• Inducer 14%
• Allograft 14%
• Phosphatidylinositol 14%
• N-terminal Domain 14%
• Akt Phosphorylation 14%
• Caspase-3 14%
• Small Tumor 14%
• Cell-penetrating Peptide 14%
• Tumor Burden 14%
• Xenograft 14%
• Tumor Cell Death 14%
• Anti-apoptotic 14%
• Tissue Type 14%
• Wortmannin 14%
• Adenocarcinoma Cells 14%
• Protein Kinase B 14%
• Apoptotic Activity 14%
• AKT Pathway 14%
• Dose-dependent 14%
• Human Peripheral Blood Mononuclear Cells (hPBMCs) 14%
• Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL) 14%
• Untreated Controls 14%
• Gemcitabine-based Chemotherapy 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Pancreas Adenocarcinoma 100%
• Protein Kinase B 100%
• Protein A 100%
• Peptide 100%
• Caspase 3 57%
• Neoplasm 42%
• Gemcitabine 42%
• Pancreas Cancer 28%
• Tumor Necrosis Factor 14%
• Phosphotransferase 14%
• Antiapoptotic 14%
• Phosphatidylinositol 14%
• Chemotherapy Regimens 14%
• Wortmannin 14%